Portland, OR –November 19, 2019 -- -- Jetblack Corp. (OTC: JTBK) (“The Company” “JTBK”) today announced more in depth details on their “first of its kind” wellness product in formulation. As a background, the recent identification of cannabinoid receptors, CB1 and CB2 receptors and their endogenous lipid ligands has started an exponential growth of studies exploring the endocannabinoid system and its regulatory functions concerning health and disease. In the past decade, the endocannabinoid...